News

SanAir Technologies Laboratory Combines with Centek Laboratories

Expands Lab Testing Capabilities into Volatile Organic Compound (VOC) Air and Soil Gas Analysis

RICHMOND, Va., SanAir Technologies Laboratory, Inc. (SanAir) today announced its merger with Syracuse, NY-based Centek Laboratories, LLC (Centek), expanding its testing capabilities into VOCs using summa cannister and/or thermal desorption tubes technology (EPA Method TO-15 and TO-17) and analyzation of samples by GC/MS coupled with cryo-focusing or thermal desorption technology.

“Like SanAir, Centek is in the environmental laboratory analysis business but with additional capabilities not currently covered by our lab,” said SanAir President Sean P. McGlynn. “Centek has been a leader in vapor intrusion technology since they opened their doors in 2003, when they helped New York State’s Department of Health and its Department of Environmental Conservation change how samples were collected and tested, improving the technology to save money and increase detection limits in the ppb (part per billion) and ppt (part per trillion) detection range. They have brought that innovative, client-focused spirit to LEED®, WELL, IgCC Certification System; Biogas, Industrial Hygiene and Product Testing. We are excited to have Centek under the SanAir umbrella.”

The combined laboratories represent a total of 70 employees in Virginia, Ohio and New York.

Centek has been working in green and sustainable technology through indoor air quality (IAQ) testing since 2009 in conjunction with the U.S. Green Building Counsel (USGBC). Current testing programs include: LEED® IEQ Credit 3.2 2009 for New Construction and Major Renovations; LEED V4; LEED 4.1; WELL; and IgCC. Centek has been doing this testing throughout the United States, Canada and Mexico and is starting to open doors overseas.

Centek also has been testing BioGas reclamation systems in landfills and wastewater treatment plants (WWTP) throughout North America. The lab identifies a complete gas profile and determines the proper treatment processes needed to meet even the most stringent biogas specifications for use as a fuel.

“We are excited about the opportunities presented by our merger with SanAir,” said Russell Pellegrino, Centek’s Technical Director. “Our companies are similarly entrepreneurial but also grounded in our foundational principles of scientific accuracy and reliability in testing.

SanAir’s resources will help Centek continue to innovate and bring cost and time-efficient sampling solutions to our clients.”

The combination of the two laboratories caps a year of expansion for SanAir that includes moving into a new headquarters location in Greater Richmond (North Chesterfield) at the former Virginia Department of Emergency Management location, and the first fully operational and accredited year of industrial hemp and medical marijuana testing for the Company’s wholly-owned subsidiary, Sativa Testing Laboratories.

Read more here.

Recent News

04/24/2024

VIPC Names Joe Benevento as President & CEO

The Board of Directors of the Virginia Innovation Partnership Corporation (VIPC) has announced that it has unanimously selected Joe Benevento as President and CEO of VIPC. Benevento has led VIPC as Interim President and CEO since September 2023 and previously served as Deputy Secretary of Commerce and Trade for the Commonwealth of Virginia since 2022.

04/23/2024

AMPEL BioSolutions Selected as Member of Prestigious Federal Health Innovation ARPA-H Network

AMPEL BioSolutions has been selected as a member – or “spoke” – of the Customer Experience Hub of ARPANET-H, a prestigious nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H).  This national effort is designed to accelerate commercialization of health breakthroughs for populations that urgently need them. The Customer Experience Hub in Dallas joins Boston

04/19/2024

ivWatch prevents IV leakage events at Frimley Health

Frimley Health NHS Foundation Trust has found that 100% of IV leakage incidents were prevented by a proprietary patient monitoring system from ivWatch, which could potentially save patients the pain or discomfort of adverse IV events. The initial two-week phase of the study, which was published in the British Journal of Nursing, found that continuous